Physician profile
Vijay Samuel
NPI 1285787739
$107,583.86
in general payments reported to CMS, 2019-2025
78 companies · $5,832 in 2025
The $5,832 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62K · 2020: $11K · 2021: $7,081 · 2022: $8,658 · 2023: $7,652 · 2024: $4,867 · 2025: $5,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Consulting Fee: $2,430 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,788.75 |
| Consulting Fee | $2,430.00 |
| Education | $132.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $29,822.45 | 2019-2025 | Mavenclad, Mavenclad |
| Genzyme Corporation | $17,004.19 | 2019-2025 | |
| Biogen, INC. | $15,780.12 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Novartis Pharmaceuticals Corporation | $9,112.90 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $6,865.40 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Abbvie INC. | $5,055.42 | 2019-2025 | Qulipta, Ubrelvy, Duopa |
| Ucb, INC. | $3,213.22 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Mdd US Operations, LLC | $2,564.52 | 2019-2024 | Gocovri, Apokyn |
| Tg Therapeutics, INC. | $1,522.25 | 2023-2025 | |
| Celgene Corporation | $1,354.00 | 2020-2025 | Zeposia |
| Genentech USA, INC. | $1,113.17 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Jazz Pharmaceuticals INC. | $1,040.56 | 2019-2024 | |
| Lilly USA, LLC | $980.32 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Amgen INC. | $925.90 | 2019-2025 | Uplizna |
| Neurocrine Biosciences, INC. | $883.05 | 2019-2025 | Ingrezza, Ongentys |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.